Literature DB >> 11549106

Ocular albinism type 1: more than meets the eye.

B Shen1, P Samaraweera, B Rosenberg, S J Orlow.   

Abstract

Ocular albinism type 1 (OA1) is an X-linked recessive disorder characterized by a severe reduction of visual acuity, and hypopigmentation of the retina that leads to nystagmus, strabismus, and photophobia/photodysphoria. Microscopic examination of both retinal pigment epithelium and skin melanocytes in OA1 reveals the presence of macrome-lanosomes, suggesting that the OA1 gene product plays a role in melanosome biogenesis. Studies of mutations identified from OA1 patients and an Oa1 knock-out mouse model further implicate OA1 protein function in the late stage of melanosome development. Because its effects are primarily limited to the eye, OA1 represents an ideal model system to study the relationship between pigmentation and visual development. Based upon sequence homology and biochemical studies, OA1 may represent a novel intracellular G-protein coupled receptor. Understanding the function of OA1 will contribute greatly to our understanding of melanosome biogenesis and the role of pigmentation in visual development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549106     DOI: 10.1034/j.1600-0749.2001.140403.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  15 in total

1.  Structural insights into human GPCR protein OA1: a computational perspective.

Authors:  Anirban Ghosh; Uddhavesh Sonavane; Sai Krishna Andhirka; Gopala Krishna Aradhyam; Rajendra Joshi
Journal:  J Mol Model       Date:  2011-09-22       Impact factor: 1.810

Review 2.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

3.  Correlation between electroretinography, foveal anatomy and visual acuity in albinism.

Authors:  Zhaohui Hu; Kai Wang; Morgan Bertsch; Taylor Dunn; Taylor Kehoe; Andrew D Kemerley; Megan Helms; Sajag Bhattarai; Wanda Pfeifer; Todd E Scheetz; Arlene V Drack
Journal:  Doc Ophthalmol       Date:  2019-03-29       Impact factor: 2.379

4.  A model for melanosome biogenesis based on the purification and analysis of early melanosomes.

Authors:  T Kushimoto; V Basrur; J Valencia; J Matsunaga; W D Vieira; V J Ferrans; J Muller; E Appella; V J Hearing
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

5.  Interaction between G Protein-Coupled Receptor 143 and Tyrosinase: Implications for Understanding Ocular Albinism Type 1.

Authors:  Elisabetta De Filippo; Anke C Schiedel; Prashiela Manga
Journal:  J Invest Dermatol       Date:  2016-10-06       Impact factor: 8.551

6.  The ocular albinism type 1 gene product, OA1, spans intracellular membranes 7 times.

Authors:  Michio Sone; Seth J Orlow
Journal:  Exp Eye Res       Date:  2007-08-29       Impact factor: 3.467

Review 7.  Pigmentation and vision: Is GPR143 in control?

Authors:  Brian S McKay
Journal:  J Neurosci Res       Date:  2018-05-14       Impact factor: 4.164

8.  The albino chick as a model for studying ocular developmental anomalies, including refractive errors, associated with albinism.

Authors:  Jodi Rymer; Vivian Choh; Shrikant Bharadwaj; Varuna Padmanabhan; Laura Modilevsky; Elizabeth Jovanovich; Brenda Yeh; Zhan Zhang; Huanxian Guan; W Payne; Christine F Wildsoet
Journal:  Exp Eye Res       Date:  2007-06-21       Impact factor: 3.467

9.  Specific interaction of Gαi3 with the Oa1 G-protein coupled receptor controls the size and density of melanosomes in retinal pigment epithelium.

Authors:  Alejandra Young; Meisheng Jiang; Ying Wang; Novruz B Ahmedli; John Ramirez; Benjamin E Reese; Lutz Birnbaumer; Debora B Farber
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Melanoregulin, product of the dsu locus, links the BLOC-pathway and OA1 in organelle biogenesis.

Authors:  Rivka A Rachel; Kunio Nagashima; T Norene O'Sullivan; Laura S Frost; Frank P Stefano; Valeria Marigo; Kathleen Boesze-Battaglia
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.